22-GI-128-RBI-PMC: Phase 1b/3 Global, Randomized, Controlled, Open-Label Trial Comparing Treatment With Actinium Ac 225 Dotatate (RYZ101) to Standard of Care (SoC) Therapy In Subjects With Inoperable, Advanced, Somatostatin Receptor Expressing (SSTR+)

Grants and Contracts Details

StatusActive
Effective start/end date10/25/227/26/23

Funding

  • RayzeBio Incorporated: $2.00